


Chenodeoxycholic Acid

Cat. No.:	HY-76847
CAS No.:	474-25-9
Molecular Formula:	C ₂₄ H ₄₀ O ₄
Molecular Weight:	393
Target:	FXR; Endogenous Metabolite; Autophagy
Pathway:	Metabolic Enzyme/Protease; Autophagy
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (127.23 mM)
 0.1 M NaOH : 50 mg/mL (127.23 mM); ultrasonic and adjust pH to 8 with NaOH
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.5445 mL	12.7226 mL	25.4453 mL
	5 mM	0.5089 mL	2.5445 mL	5.0891 mL
	10 mM	0.2545 mL	1.2723 mL	2.5445 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 20% HP-β-CD in saline
Solubility: ≥ 20 mg/mL (50.89 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 2.5 mg/mL (6.36 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.36 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.36 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Chenodeoxycholic acid (CDCA) and Deoxycholic acid (DCA) both inhibit 11 beta HSD2 with IC_{50} values of 22 mM and 38 mM, respectively and causes cortisol-dependent nuclear translocation and increases transcriptional activity of mineralocorticoid receptor (MR)^[1]. Chenodeoxycholic acid is able to stimulate Ishikawa cell growth by inducing a significant increase in Cyclin D1 protein and mRNA expression through the activation of the membrane G protein-coupled receptor (TGR5)-dependent pathway^[2]. Chenodeoxycholic acid (CDCA) induces LDL receptor mRNA levels approximately 4 fold and mRNA levels for HMG-CoA reductase and HMG-CoA synthase two fold in a cultured human hepatoblastoma cell line, Hep G2^[3]. Chenodeoxycholic acid-induced Isc is inhibited ($\geq 67\%$) by Bumetanide, $BaCl_2$, and the cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor CFTRinh-172. Chenodeoxycholic acid-stimulated Isc is decreased 43% by the adenylate cyclase inhibitor MDL12330A and Chenodeoxycholic acid increases intracellular cAMP concentration^[4]. Chenodeoxycholic acid treatment activates C/EBP β , as shown by increases in its phosphorylation, nuclear accumulation, and expression in HepG2 cells. Chenodeoxycholic acid enhances luciferase gene transcription from the construct containing -1.65-kb GSTA2 promoter, which contains C/EBP response element (pGL-1651). Chenodeoxycholic acid treatment activates AMP-activated protein kinase (AMPK), which leads to extracellular signal-regulated kinase 1/2 (ERK1/2) activation, as evidenced by the results of experiments using a dominant-negative mutant of AMPK α and chemical inhibitor^[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

Briefly, transfected HEK-293 cells, incubated in charcoal-treated Dulbecco's modified Eagle's medium for 24 h, are washed once with Hanks' solution and resuspended in a buffer containing 100 mM NaCl, 1 mM $MgCl_2$, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose, 20 mM Tris-HCl, pH 7.4. Cells are lysed by freezing in liquid nitrogen. Dehydrogenase activity is measured in a final volume of 20 μ L containing the appropriate concentration of bile acid, 30 nCi of [³H]cortisol, and unlabeled cortisol to a final concentration of 50 nM. The reaction is started by mixing cell lysate with the reaction mixture. Alternatively, endoplasmic reticulum microsomes are prepared from transfected HEK-293 cells and incubated with reaction mixture containing various concentrations of cortisol and CDCA. Incubation proceeded for 20 min, and the conversion of cortisol to cortisone is determined by thin layer chromatography (TLC). Because of the inaccuracy of the TLC method at low conversion rates and the end-product inhibition of 11 β HSD2 at conversion rates higher than 60-70%, only conversion rates between 10 and 60% are considered for calculation. The inhibitory constant IC_{50} is evaluated using the curve-fitting program. Results are expressed as means \pm S.E. and consist of at least four independent measurements.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay ^[1]

The cell viability is analyzed by incubating transfected HEK-293 cells and CHO cells for 1 h with the corresponding concentration of bile acid and staining with trypan blue. The toxicity of bile acids is analyzed using the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) according to the cell proliferation kit I. No significant differences between control and bile acid-treated cells are obtained in both tests.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Res. 2019 Mar;29(3):193-205.
- Cell Host Microbe. 2024 Jan 11:S1931-3128(23)00510-3.
- Research (Wash D C). 2022 Nov 2;2022:9784081.
- Sci Total Environ. 2023 Apr 15.
- Phytomedicine.2023 Sep;118:154971.

See more customer validations on www.MedChemExpress.com

REFERENCES

-
- [1]. Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. *J Biol Chem.* 2002 Jul 19;277(29):26286-92
- [2]. Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. *Cell Cycle.* 2012 Jul 15;11(14):2699-710
- [3]. Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. *Biochem Biophys Res Commun.* 1995 Mar 8;208(1):405-11.
- [4]. Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. *Am J Physiol Cell Physiol.* 2013 Aug 15;305(4):C447-56
- [5]. Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β . *Drug Metab*
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA